Ładuje się......
HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab
Ovarian clear cell adenocarcinoma (CCA) is generally chemo‐resistant. Recently the poor prognosis and resistance to chemotherapeutic agents of HER2/neu over‐expressing tumors have become clear. Thus, we investigated the expression level of HER2 in surgically resected CCA and ovarian serous adenocarc...
Zapisane w:
| Wydane w: | Jpn J Cancer Res |
|---|---|
| Główni autorzy: | , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Blackwell Publishing Ltd
2002
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5926901/ https://ncbi.nlm.nih.gov/pubmed/12460467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2002.tb01231.x |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|